Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Clinical trial NCT04777162 · UNKNOWN

Trial details

NCT number: NCT04777162
Sponsor: Peking University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric Cancer Colo-rectal Cancer

Start date: 2021-03-01
Primary completion: 2023-01-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.